Navigation Links
Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis
Date:3/4/2010

To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.

In vitro cultivated ICCBco is composed of Calculus Bovis, Chinese Paris Rhizome, polygonum cuspidatum, appendiculate cremastra pseudobulb, frankincense, and myrrh, and has the functions of clearing away heat and toxic materials, removing blood stasis, reducing swelling, eliminating blood stasis and promoting tissue regeneration, according to the principle of traditional Chinese medicine. However, the topic has not been unequivocally addressed.

A research article published on February 14, 2010 in the World Journal of Gastroenterology addresses this question. The group led by Tao Li, MD, evaluated the efficacy of ICCBco in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model. They explored the pathogenesis of portal hypertension and the prevention and treatment of its pulmonary complications (hepatopulmonary syndrome, pulmonary fibrosis, pulmonary hypertension, pulmonary venous hypertension) from a new perspective of portal hypertensive vascular disease. Calculus Bovis is a Class 1 new Chinese medicine developed by Wuhan Tongji Hospital with independent intellectual property rights, is a treasure of traditional Chinese medicine. To investigate its role in the treatment of schistosomiasis-induced pulmonary complications of portal hypertension has far-reaching significance.

The successful development of Calculus Bovis and the preliminary study on portal hypertensive pulmonary lesions caused by schistosomiasis suggest that it is of great significance and prospects for further basic and clinical research, development and clinical application of new drugs and preparations to treat portal hypertensive pulmonary lesions induced by schistosomiasis.


'/>"/>

Contact: Jin-Lei Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. New Alzheimers Prevention Efforts, and Non-Drug Treatments, Featured at 25th Conference of Alzheimers Disease International
2. Montecatini Eating Disorders Program Announces 'Log In & Learn' Webinar Series for Treatment Professionals
3. Targeting leukemia cells gene addiction presents new strategy for treatment
4. BioCosmetic Center Utilizes FDA Approved Fractional Laser Treatment for Stretch Marks
5. PINC trial launched to test new treatment for pre-invasive breast cancer
6. New Treatment Eyed for Deadly Pancreatic Cancer
7. Connecticut Governor Jodi Rell Honors Mountainside Addiction Treatment Center for its Twelve Years of Operating in Connecticut
8. Blacks less likely to know they have heart condition or to use treatment for it, says Mayo Clinic
9. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
10. New CASA* Report Finds: 65 Percent of All U.S. Inmates Meet Medical Criteria for Substance Abuse Addiction, Only 11 Percent Receive Any Treatment
11. Groundbreaking Study Using Ultrasound for the Treatment of Intracerebral and Intraventricular Hemorrhage Stroke Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
Breaking Medicine Technology: